Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis

This publication has 28 references indexed in Scilit:

• CD69, HLA-DR and the IL-2R Identify Persistently Activated T Cells in Psoriasis Vulgaris Lesional Skin: Blood and Skin Comparisons by Flow Cytometry
  Journal of Autoimmunity, 2000
• Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions
  Journal of Clinical Investigation, 1999
• The Majority of Epidermal T Cells in Psoriasis Vulgaris Lesions can Produce Type 1 Cytokines, Interferon-γ, Interleukin-2, and Tumor Necrosis Factor-α, Defining TC1 (Cytotoxic T Lymphocyte) and TH1 Effector Populations:1 a Type 1 Differentiation Bias is also Measured in Circulating Blood T Cells in Psoriatic Patients
  Journal of Investigative Dermatology, 1999
• Treatment of Recalcitrant Plaque Psoriasis with a Humanized Non-depleting Antibody to CD4
  Journal of Autoimmunity, 1998
• IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.
  Journal of Clinical Investigation, 1998
• Rediscovering mycophenolic acid: A review of its mechanism, side effects, and potential uses
  Journal of the American Academy of Dermatology, 1997
• Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy.
  Journal of Clinical Investigation, 1997
• Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
  Nature, 1996
• FK506 in the treatment of inflammatory skin disease: promises and perspectives
  Immunology Today, 1996
• INCREASED EXPRESSION OF IL-4 AND IL-10 AND DECREASED EXPRESSION OF IL-2 AND INTERFERON-γ IN LONG-SURVIVING MOUSE HEART ALLOGRAFTS AFTER BRIEF CD4-MONOCLONAL ANTIBODY THERAPY1,2
  Transplantation, 1995